Key result
Current post-TAVI antithrombotics carry high bleeding rates and rely on weak evidence.
Why the study?
Post-TAVI valve thrombosis and cerebral ischaemic events remain significant issues, while current preventive antithrombotic therapies are based on weak evidence and carry high bleeding risks.
This review provides a comprehensive overview of the mechanisms, current guidelines, and future directions for managing thromboembolic and bleeding complications following TAVI.
No takes yet. Share an insight, caveat, or question.
Current regimens warrant bleeding caution post-TAVI; leaves open safer paradigms for dedicated RCTs.
Ranasinghe et al. (2019) conducted a review in Severe aortic stenosis undergoing TAVI. Antithrombotic treatments post-TAVI was evaluated. Current antithrombotic treatments for preventing post-TAVI thrombosis are based on weak evidence and associated with high bleeding rates, highlighting the need for novel, safer therapeutic paradigms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: